Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - piroxicam, quantity: 20 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; sodium starch glycollate; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin - symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - piroxicam, quantity: 10 mg - capsule, hard - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; sodium starch glycollate; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; iron oxide red; gelatin - symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine, quantity: 10 mg - capsule, hard - excipient ingredients: mannitol; gelatin; titanium dioxide; magnesium stearate; indigo carmine; butan-1-ol; shellac; iron oxide black - (1) brain tumours (primary and secondary). (2) hodgkin's disease (as secondary therapy). lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. ceenu containing combinations should be used as alternative therapy in the treatment of disseminated hodgkin's disease in patients refractory to other established treatment regimens.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine, quantity: 40 mg - capsule, hard - excipient ingredients: gelatin; indigo carmine; magnesium stearate; mannitol; titanium dioxide; iron oxide yellow; butan-1-ol; shellac; iron oxide black - (1) brain tumours (primary and secondary). (2) hodgkin's disease (as secondary therapy). lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. ceenu containing combinations should be used as alternative therapy in the treatment of disseminated hodgkin's disease in patients refractory to other established treatment regimens.

Izraelis - anglų - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; povidone; iron oxide red; mannitol; titanium dioxide; croscarmellose sodium; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose; gelatin; mannitol; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 12.5 mg - capsule - excipient ingredients: titanium dioxide; povidone; microcrystalline cellulose; iron oxide red; gelatin; mannitol; magnesium stearate; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: magnesium stearate; gelatin; croscarmellose sodium; mannitol; povidone; microcrystalline cellulose; iron oxide red; titanium dioxide; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: gelatin; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; povidone; mannitol; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).